A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia by Aaron D. Schimmer (150194)

“…Initial obatoclax dose was 30 mg/day (3 h×3 d; n = 3). Obatoclax was increased to 45 mg/day (3 h×3 d) if ≤1 patient had a dose-limiting toxicity (DLT) and decreased to 20 mg/day (3 h×3 d) if DLT occurred in ≥2 patients. …”

Percentage of normal/intermediate/poor metabolizers, or persons with decreased or poor transporter function of SLCO1B1 or reduced expression of VKORC1, showing high proportions of... by Riccardo Proietti (15332861)

Reciprocal increase in 5mC and decrease in 5hmC at the pregnancy-associated gene clusters in placentas of obese compared to lean mothers. by Kohzoh Mitsuya (4521304)

“…<p>(A) Reciprocal increase in 5mC and decrease in 5hmC at the <i>GH-CSH</i> gene cluster on human chromosome 17q24. …”

Stroma decreases spheroid size by decreasing cell width. by Karen F. Chambers (224337)

Silencing JARID1B decreases epithelial to mesenchymal transition (EMT). by Yung-Ting Kuo (736349)

JNK inhibitor AS601245 significantly rescued the decrease in p-FOXO3a and attenuated FOXO3a translocation into nucleus after HI with no influence on p-Akt. by Deyuan Li (769599)

Galiellalactone decreases the proportion of ALDH+ prostate cancer cells in vitro and the ALDH1A1 expression in vivo. by Rebecka Hellsten (348459)

“…<p>A. DU145 and LNCaP-IL6 cells were treated with galiellalactone (5–50 µM) for 24 h and subjected to ALDEFLUOR® assay. …”

Eltrombopag markedly decreases levels of ROS in MOLM14 cells. by Anna Kalota (7415)

“…B) Graphic presentation of ROS levels measured by flow cytometry in cells treated with E (5 μM) or DPI (25 μM), an inhibitor of NADPH oxidase known to decrease an intracellular level of ROS, or untreated (CTR) cells. …”

Aged blood factors decrease cellular responses associated with delayed gingival wound repair by María Paz Saldías (4430032)

“…<div><p>Aging is a gradual biological process characterized by a decrease in cell and organism functions. …”

TG6-44 treatment leads to decrease in A/X31-induced cell death in PBMC. by Juan A. De La Cruz (11154187)

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited pupicidal activity against pupae of <i>A</i>. <i>albopictus</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited adulticidal activity against adult of <i>A</i>. <i>albopictus</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

The response of the <i>A</i>. <i>albopictus</i> larval Glutathione S-transferase (GST) enzyme increased 7.8-fold in response to <i>M</i>. <i>robertsii</i>-derived copper nanopartic... by Perumal Vivekanandhan (4863484)

Subjects:

Schematic diagram of entomopathogen derived copper nanoparticles (CuNPs) and their toxic effects on target and non-target species. by Perumal Vivekanandhan (4863484)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited larvicidal activity against larvae of <i>A</i>. <i>albopictu</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited minimal toxicity effects against <i>E</i>. <i>eugeniae</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited minimal toxicity effects against <i>A</i>. <i>salina</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

The increases and decreases in year-to-year migration. by Bruce A. Desmarais (334821)

“…<p>The upper-left and upper-right plots respectively show the largest 5% of decreases and increases from one state to another; the width of the line corresponds to the magnitude of the exodus. …”

Deletion of <i>Kdm5b</i> in DCs leads to increased cytokine production and decreased Th2 pathology <i>in vivo</i>. by Catherine Ptaschinski (756139)

Roscovitine decreases transcription of fibrogenic mediators. by Richard A. Steinman (117481)

“…<p><b>A</b>. Roscovitine decreases mRNA expression of <i>CTGF</i>, collagen and fibronectin. …”